BNTX logo

BioNTech SE

BNTX
Healthcare|Biotechnology|DE
$87.51
+1.65 (+1.92%)
DCF Value
$46.34
Tangible Book / Share
$64.71
Cash / Share
$58.79
Next Earnings Report
Mar 9, 2027
EPS est. -$1.90 · Revenue est. $445.5M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (49)

Dec 2026
Est. completion
P1Non Small Cell Lung Cancer
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Jan 2027
Est. completion
P2Neuroendocrine Neoplasm
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Apr 2027
Est. completion
P3COVID-19 Vaccines
A Study of COVID-19 Vaccine(s) in Children and Adults
May 2027
Est. completion
P2CRC (Colorectal Cancer)
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
May 2027
Est. completion
P3SCLC
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Jun 2027
Est. completion
P2Mpox (Monkeypox)
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
Jun 2027
Est. completion
P2Extensive-stage Small-cell Lung Cancer
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Jul 2027
Est. completion
P3Triple Negative Breast Cancer(TNBC)
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Jul 2027
Est. completion
P1Lymphocytic Leukemia
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Aug 2027
Est. completion
P1P2HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Aug 2027
Est. completion
P1Malignant Solid Tumor
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Aug 2027
Est. completion
P1P2Advanced Solid Tumor
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Aug 2027
Est. completion
P4COVID-19 Vaccines
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
Aug 2027
Est. completion
P3Non Small Cell Lung Cancer
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Nov 2027
Est. completion
P1P2Advanced Solid Tumor
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Nov 2027
Est. completion
P2Muscle-invasive Urothelial Carcinoma
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Dec 2027
Est. completion
P3HER2-positive Breast Cancer
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
Dec 2027
Est. completion
P1P2Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Dec 2027
Est. completion
P2Pancreatic Ductal Adenocarcinoma (PDAC)
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Jan 2028
Est. completion
P2Recurrent Glioblastoma
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Awaiting Results (10)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378
Oct 2026
P1P2
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT05918133
Oct 2026
P1
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
NCT05432583
Aug 2026
P1
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183
Aug 2026
P3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337
Mar 2026
P1P2
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
NCT05547464
Dec 2025
P1P2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599
Apr 2025
P2
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
NCT05879068
Sep 2024
P2
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
NCT05756972
May 2024
P2
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
NCT05844150

Recent Press Releases

SEC Filings (106)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 3, 20266-KForeign issuer reportDocumentIndex
Nov 3, 20266-KForeign issuer reportDocumentIndex
Oct 26, 20266-KForeign issuer reportDocumentIndex
Oct 26, 20266-KForeign issuer reportDocumentIndex
Oct 22, 20266-KForeign issuer reportDocumentIndex
Oct 19, 20266-KForeign issuer reportDocumentIndex
Oct 13, 20266-KForeign issuer reportDocumentIndex
Sep 18, 20266-KForeign issuer reportDocumentIndex
Sep 14, 20266-KForeign issuer reportDocumentIndex
Aug 28, 20266-KForeign issuer reportDocumentIndex
Aug 27, 20266-KForeign issuer reportDocumentIndex
Aug 20, 20266-KForeign issuer reportDocumentIndex
Aug 4, 20266-KForeign issuer reportDocumentIndex
Aug 4, 20266-KForeign issuer reportDocumentIndex
Aug 3, 20266-KForeign issuer reportDocumentIndex
Jul 30, 202620-F/AAnnual report (foreign)DocumentIndex
Jul 29, 20266-KForeign issuer reportDocumentIndex
Jun 8, 20266-KForeign issuer reportDocumentIndex
Jun 1, 20266-KForeign issuer reportDocumentIndex
May 22, 20266-KForeign issuer reportDocumentIndex
May 15, 20266-KForeign issuer reportDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 7, 20266-KForeign issuer reportDocumentIndex
May 5, 20266-KForeign issuer reportDocumentIndex
May 5, 20266-KForeign issuer reportDocumentIndex
Apr 13, 20266-KForeign issuer reportDocumentIndex
Apr 2, 20266-KForeign issuer reportDocumentIndex
Apr 1, 202620-F/AAnnual report (foreign)DocumentIndex
Mar 24, 20266-KForeign issuer reportDocumentIndex
Mar 10, 202620-FAnnual report (foreign)DocumentIndex
Mar 10, 20266-KForeign issuer reportDocumentIndex
Mar 10, 20266-KForeign issuer reportDocumentIndex
Jan 28, 20266-KForeign issuer reportDocumentIndex
Jan 14, 20266-KForeign issuer reportDocumentIndex
Jan 12, 20266-KForeign issuer reportDocumentIndex
Jan 6, 20266-KForeign issuer reportDocumentIndex
Dec 18, 2025SC TO-T/ATender offerDocumentIndex
Dec 18, 20256-KForeign issuer reportDocumentIndex
Dec 9, 20256-KForeign issuer reportDocumentIndex